Gastric cancer is one of the most common malignant tumors worldwide. China is a large country in which gastric cancer ranks among the top 3 malignant tumors in terms of incidence, and related morbidity and mortality 1 . In the past 20 years, China has made the most outstanding achievements in the diagnosis and treatment of gastric cancer among countries worldwide. The overall 5-year survival rate of patients in China has increased by nearly 10% 2 . However, early gastric cancer accounts for only 20% of clinically confirmed cases, the overall effects of therapies for gastric cancer still must be improved 3 . The REGATTA study has confirmed that palliative surgery cannot improve the long-term survival of patients with stage IV gastric cancer 4 . To improve patient survival, multidisciplinary treatment has recently received substantial attention. Gastrointestinal surgeons in Japan have administered systemic chemotherapy to some patients with stage IV gastric cancer and performed R0 gastrectomy on some patients with down-staging disease, to potentially achieve long-term survival. Conversion therapy for gastric cancer is defined as a surgical treatment aimed at R0 resection after chemotherapy for tumors that are technically and/or oncologically unresectable, or marginally resectable. Yoshida et al. 5 have proposed classification categories for stage IV gastric cancer according to the biology of the tumor burden. According to this classification, categories 2, 3, and 4 have been defined as marginally resectable or unresectable metastasis, macroscopic peritoneal dissemination, and peritoneal disease and other organ metastasis, respectively.